التفاصيل البيبلوغرافية
| العنوان: |
Safety and efficacy of benralizumab in elderly subjects with severe asthma. |
| المؤلفون: |
Valverde-Monge, Marcela1,2 (AUTHOR), Cárdenas, Remedios3 (AUTHOR) reme1975@hotmail.com, García-Moguel, Ismael4,5 (AUTHOR), Rosado, Ana6 (AUTHOR), Gandolfo-Cano, Mar7,8 (AUTHOR), Echarren, Teresa Robledo9,10 (AUTHOR), Moro-Moro, María del Mar11 (AUTHOR), Reaño Martos, María del Mar12 (AUTHOR), Pineda-Pineda, Rafael13 (AUTHOR), Arroba, Cristina Martin-Arriscado14 (AUTHOR), Domínguez-Ortega, Javier15 (AUTHOR) |
| المصدر: |
Journal of Asthma. Mar2024, Vol. 61 Issue 3, p232-237. 6p. |
| مصطلحات موضوعية: |
*ASTHMA, *OLDER people, *OLDER patients, *DEATH rate, *WHEEZE |
| مستخلص: |
The prevalence of asthma in adults >65 years old is approximately 12–14%, and 10% have severe asthma. A higher mortality rate is observed in subjects with asthma >65 years old and especially >80 years old. To analyze the effectiveness and safety of at least three doses of benralizumab in a subgroup of elderly subjects (>65 years old) with uncontrolled severe eosinophilic asthma in real-life conditions. This was a retrospective multicenter study (AUTOBENRA study) conducted in 9 hospitals that included 72 patients aged >18 years old with uncontrolled severe asthma based on the Spanish Asthma Guidelines who were treated with at least three doses of benralizumab, self-administered at home since before April 30, 2021. The recruitment period ended on October 1, 2021. Written consent was obtained before the study commencement. In this subanalysis, we compared the results between patients >65 years old and patients <65 years old. A total of 72 subjects with severe asthma were screened, and 54 were included (MD: 57.3 ± 10 years old). There were 12 subjects aged >65 years old [MD: 69.8 ± 4.3 years old (minimum: 65 years old; maximum: 83 years old)]. Subjects >65 years old experienced statistically significant improvement in lung function, ACT and mini-AQLQ with benralizumab. Additionally, 9 patients (75%) experienced no asthma exacerbation (p = 0.0047), half (3/6) were able to stop OCS (p = 0.08), and no adverse effects with benralizumab were reported during the 20 months of follow-up. In patients aged >65 years old, benralizumab was an effective and safe therapy for severe eosinophilic asthma in our study, with no significant differences from the younger subgroup. This is especially important since they are a group with numerous comorbidities, medications and worse quality of life. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
